BIO-RAD LABORATORIES-A (BIO) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:BIO - US0905722072 - Common Stock
305.27 USD
+2.28 (+0.75%)
305.27 USD
0 (0%)
Taking everything into account, BIO scores 4 out of 10 in our fundamental rating. BIO was compared to 57 industry peers in the Life Sciences Tools & Services industry. BIO has an excellent financial health rating, but there are some minor concerns on its profitability. BIO is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
BIO had positive earnings in the past year.
BIO had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: BIO reported negative net income in multiple years.
BIO had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
BIO has a Return On Assets (-6.97%) which is in line with its industry peers.
BIO has a Return On Equity (-10.03%) which is in line with its industry peers.
The Return On Invested Capital of BIO (2.26%) is better than 61.40% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BIO is significantly below the industry average of 13.99%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROIC | 2.26% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
Looking at the Operating Margin, with a value of 10.27%, BIO is in the better half of the industry, outperforming 70.18% of the companies in the same industry.
In the last couple of years the Operating Margin of BIO has remained more or less at the same level.
The Gross Margin of BIO (52.42%) is better than 63.16% of its industry peers.
In the last couple of years the Gross Margin of BIO has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BIO is destroying value.
Compared to 1 year ago, BIO has less shares outstanding
The number of shares outstanding for BIO has been reduced compared to 5 years ago.
The debt/assets ratio for BIO is higher compared to a year ago.
2.2 Solvency
BIO has an Altman-Z score of 3.37. This indicates that BIO is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.37, BIO is doing good in the industry, outperforming 68.42% of the companies in the same industry.
BIO has a debt to FCF ratio of 3.57. This is a good value and a sign of high solvency as BIO would need 3.57 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.57, BIO is in the better half of the industry, outperforming 77.19% of the companies in the same industry.
A Debt/Equity ratio of 0.18 indicates that BIO is not too dependend on debt financing.
BIO has a Debt to Equity ratio of 0.18. This is comparable to the rest of the industry: BIO outperforms 57.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Altman-Z | 3.37 |
ROIC/WACC0.21
WACC10.53%
2.3 Liquidity
BIO has a Current Ratio of 5.44. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
BIO's Current ratio of 5.44 is amongst the best of the industry. BIO outperforms 85.96% of its industry peers.
BIO has a Quick Ratio of 3.94. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of BIO (3.94) is better than 68.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 |
3. Growth
3.1 Past
The earnings per share for BIO have decreased by -1.90% in the last year.
Measured over the past 5 years, BIO shows a small growth in Earnings Per Share. The EPS has been growing by 7.84% on average per year.
The Revenue has decreased by -0.88% in the past year.
BIO shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.11% yearly.
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
3.2 Future
The Earnings Per Share is expected to decrease by -2.66% on average over the next years.
The Revenue is expected to grow by 1.26% on average over the next years.
EPS Next Y-2.19%
EPS Next 2Y-0.04%
EPS Next 3Y3.67%
EPS Next 5Y-2.66%
Revenue Next Year0.15%
Revenue Next 2Y1.2%
Revenue Next 3Y2.07%
Revenue Next 5Y1.26%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 29.61 indicates a quite expensive valuation of BIO.
BIO's Price/Earnings ratio is a bit cheaper when compared to the industry. BIO is cheaper than 75.44% of the companies in the same industry.
When comparing the Price/Earnings ratio of BIO to the average of the S&P500 Index (26.60), we can say BIO is valued inline with the index average.
A Price/Forward Earnings ratio of 29.63 indicates a quite expensive valuation of BIO.
Based on the Price/Forward Earnings ratio, BIO is valued a bit cheaper than 68.42% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.23. BIO is valued slightly more expensive when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.61 | ||
| Fwd PE | 29.63 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, BIO is valued a bit cheaper than the industry average as 77.19% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.45 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)3.78
EPS Next 2Y-0.04%
EPS Next 3Y3.67%
5. Dividend
5.1 Amount
No dividends for BIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
305.27
+2.28 (+0.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners92.44%
Inst Owner Change1.8%
Ins Owners8.18%
Ins Owner Change0%
Market Cap8.23B
Revenue(TTM)2.56B
Net Income(TTM)-675.90M
Analysts76
Price Target362.1 (18.62%)
Short Float %4.91%
Short Ratio4.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.41%
Min EPS beat(2)15.74%
Max EPS beat(2)49.07%
EPS beat(4)4
Avg EPS beat(4)25.97%
Min EPS beat(4)0.1%
Max EPS beat(4)49.07%
EPS beat(8)8
Avg EPS beat(8)30.43%
EPS beat(12)9
Avg EPS beat(12)18.8%
EPS beat(16)12
Avg EPS beat(16)18.31%
Revenue beat(2)1
Avg Revenue beat(2)2.07%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)4.87%
Revenue beat(4)2
Avg Revenue beat(4)0.63%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)-0.13%
Revenue beat(12)3
Avg Revenue beat(12)-1.59%
Revenue beat(16)5
Avg Revenue beat(16)-1.12%
PT rev (1m)0%
PT rev (3m)8.45%
EPS NQ rev (1m)-2.73%
EPS NQ rev (3m)-2.34%
EPS NY rev (1m)-0.6%
EPS NY rev (3m)3.49%
Revenue NQ rev (1m)-1.14%
Revenue NQ rev (3m)-1.25%
Revenue NY rev (1m)-0.27%
Revenue NY rev (3m)-0.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.61 | ||
| Fwd PE | 29.63 | ||
| P/S | 3.22 | ||
| P/FCF | 24.45 | ||
| P/OCF | 16.75 | ||
| P/B | 1.22 | ||
| P/tB | 1.43 | ||
| EV/EBITDA | N/A |
EPS(TTM)10.31
EY3.38%
EPS(NY)10.3
Fwd EY3.37%
FCF(TTM)12.48
FCFY4.09%
OCF(TTM)18.22
OCFY5.97%
SpS94.83
BVpS249.79
TBVpS213.93
PEG (NY)N/A
PEG (5Y)3.78
Graham Number240.72
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROCE | 2.86% | ||
| ROIC | 2.26% | ||
| ROICexc | 2.67% | ||
| ROICexgc | 3.06% | ||
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% | ||
| FCFM | 13.17% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexgc growth 3Y8.21%
ROICexgc growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score5
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 6.05% | ||
| Interest Coverage | -5.71 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 | ||
| Altman-Z | 3.37 |
F-Score5
WACC10.53%
ROIC/WACC0.21
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
EPS Next Y-2.19%
EPS Next 2Y-0.04%
EPS Next 3Y3.67%
EPS Next 5Y-2.66%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
Revenue Next Year0.15%
Revenue Next 2Y1.2%
Revenue Next 3Y2.07%
Revenue Next 5Y1.26%
EBIT growth 1Y-23.49%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year33.67%
EBIT Next 3Y14.51%
EBIT Next 5Y6.94%
FCF growth 1Y50.11%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y31.59%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%
BIO-RAD LABORATORIES-A / BIO FAQ
What is the fundamental rating for BIO stock?
ChartMill assigns a fundamental rating of 4 / 10 to BIO.
Can you provide the valuation status for BIO-RAD LABORATORIES-A?
ChartMill assigns a valuation rating of 2 / 10 to BIO-RAD LABORATORIES-A (BIO). This can be considered as Overvalued.
What is the profitability of BIO stock?
BIO-RAD LABORATORIES-A (BIO) has a profitability rating of 4 / 10.
Can you provide the expected EPS growth for BIO stock?
The Earnings per Share (EPS) of BIO-RAD LABORATORIES-A (BIO) is expected to decline by -2.19% in the next year.